Kim Rodriguez expected to follow her mom’s career in medicine. But she got bit by the Medtech Bug early and enjoyed a string of sales success at companies of nearly every size including Concentric, Spectranetics, and Guidant. But three years ago she got recruited to be CEO of a company that was rich in promising technologies as well as business challenges. In just three years, Rodriguez and her team at Acessa pulled out of the tail spin, secured FDA approval and a CPT code and now are building a promising women’s health company. In this episode, she’ll share how aspiring execs should ante up.
President, CEO and Co-Founder of Acessa Health
Kim Rodriguez is the President, CEO & Co-Founder of Acessa Health. Previously, she served as President & CEO of Halt Medical. Prior to Halt, she was Senior Vice President of the Vascular Intervention business unit at Spectranetics, a publicly-traded cardiovascular company acquired by Royal Philips for $2.2B. Before that, she served in a series of global senior leadership roles across sales, marketing, therapy development and general business management at Johnson & Johnson, Blockade Medical acquired by Balt International, Concentric Medical acquired by Stryker Neurovascular, Guidant Corporation acquired by Abbott Vascular and Microvena acquired by ev3. Over the course of a 20+ year career in cardiology, radiology, vascular surgery, neurology and women’s health, Kim has been involved in the commercialization of dozens of innovative MedTech technologies and M&A transactions. Kim received her Executive MBA at the University of Southern California Marshall School of Business and BS in Management from Pepperdine University.
Meet Our Host
A follower and fan of medtech for nearly two decades, Tom Salemi is the former bureau chief, venture capital, at Elsevier Business Intelligence, where he oversaw coverage of venture investments in medtech.